Halozyme Therapeutics, Inc. (NASDAQ:HALO) Holdings Boosted by Raymond James & Associates

Raymond James & Associates lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 87.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 273,591 shares of the biopharmaceutical company’s stock after purchasing an additional 127,330 shares during the quarter. Raymond James & Associates owned about 0.21% of Halozyme Therapeutics worth $15,660,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Wellington Management Group LLP lifted its stake in Halozyme Therapeutics by 16.1% in the fourth quarter. Wellington Management Group LLP now owns 180,856 shares of the biopharmaceutical company’s stock valued at $6,684,000 after buying an additional 25,125 shares during the last quarter. Park Avenue Securities LLC lifted its position in Halozyme Therapeutics by 17.3% in the 1st quarter. Park Avenue Securities LLC now owns 8,294 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 1,225 shares during the last quarter. State of Michigan Retirement System lifted its position in Halozyme Therapeutics by 2.2% in the 1st quarter. State of Michigan Retirement System now owns 32,438 shares of the biopharmaceutical company’s stock valued at $1,320,000 after purchasing an additional 700 shares during the last quarter. Norden Group LLC boosted its stake in Halozyme Therapeutics by 1,817.3% during the 1st quarter. Norden Group LLC now owns 167,284 shares of the biopharmaceutical company’s stock valued at $6,805,000 after purchasing an additional 158,559 shares during the period. Finally, Retirement Systems of Alabama grew its position in Halozyme Therapeutics by 0.3% in the 1st quarter. Retirement Systems of Alabama now owns 165,881 shares of the biopharmaceutical company’s stock worth $6,748,000 after purchasing an additional 436 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Activity

In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $55.72, for a total transaction of $557,200.00. Following the completion of the sale, the director now directly owns 89,755 shares of the company’s stock, valued at approximately $5,001,148.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Matthew L. Posard sold 9,881 shares of Halozyme Therapeutics stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the transaction, the director now owns 69,874 shares in the company, valued at approximately $4,031,729.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Matthew L. Posard sold 10,000 shares of the stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $55.72, for a total value of $557,200.00. Following the completion of the sale, the director now directly owns 89,755 shares of the company’s stock, valued at approximately $5,001,148.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 89,881 shares of company stock valued at $5,169,834 over the last three months. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $49.25 on Friday. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The business’s 50-day moving average price is $57.99 and its 200 day moving average price is $51.58. Halozyme Therapeutics, Inc. has a 52-week low of $32.95 and a 52-week high of $65.53. The firm has a market cap of $6.24 billion, a P/E ratio of 19.09, a PEG ratio of 0.50 and a beta of 1.27.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The company had revenue of $231.40 million for the quarter, compared to analysts’ expectations of $204.94 million. During the same quarter in the previous year, the company posted $0.68 EPS. The business’s revenue was up 4.7% compared to the same quarter last year. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on HALO. The Goldman Sachs Group lifted their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a report on Monday, July 22nd. Wells Fargo & Company downgraded Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $58.00 to $62.00 in a research note on Monday, October 7th. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Benchmark restated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Finally, TD Cowen increased their target price on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $60.44.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.